As a founding partner and initial funder of the Collaborative Trajectory Analysis Project (cTAP), CureDuchenne is proud to support an important advancement for the Duchenne community: a novel prognostic score that helps predict when an individual may lose the ability to walk. This advancement can help clinicians better anticipate care needs and support families while enabling more precise clinical trials and accelerating the development of new therapies.
CureDuchenne contributed vital patient data that helped make this research possible. Advancing research like this is central to our mission of accelerating research, improving care, and bringing effective treatments to every individual living with Duchenne.
Learn more: https://www.businesswire.com/news/home/20260615221008/en/cTAP-Announces-Novel-Prognostic-Score-Developed-for-Duchenne-Muscular-Dystrophy-Patients-Offers-Improved-Prediction-of-Loss-of-Ambulation
The post cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation appeared first on CureDuchenne.